logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Lenvatinib in combination with pembrolizumab for advanced/unresectable hepatocellular carcinoma – first-line

< Back

Lenvatinib in combination with pembrolizumab for advanced/unresectable hepatocellular carcinoma – first-line

Drugs

Cancer and Palliative Care

January 2021


Lenvatinib in combination with pembrolizumab is in clinical development for the treatment of hepatocellular carcinoma (HCC), which is cancer that originally develops in the liver and accounts for nine in ten primary liver cancer cases. Advanced or unresectable HCC occurs when the cancer has spread to lymph nodes or to other organs and cannot be treated by surgery alone. It is often diagnosed late in life and has a poor prognosis. It is a debilitating condition with many distressing symptoms, including pain, digestive problems and weight loss. There are currently limited treatment options, yet research has suggested combining different drugs may improve survival for HCC patients.
Lenvatinib is an orally administered tyrosine kinase inhibitor that targets several different growth factor receptors. By blocking these receptors, lenvatinib can reduce tumour growth. Pembrolizumab is an intravenously administered drug that improves the activity of the immune system to kill cancer cells. If licensed pembrolizumab in combination with lenvatinib, could provide an additional first-line treatment option for patients with advanced or unresectable HCC.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts